Catalyst Pharmaceuticals, Inc. $CPRX Shares Acquired by Systematic Financial Management LP

Systematic Financial Management LP boosted its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 3.4% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 747,515 shares of the biopharmaceutical company’s stock after acquiring an additional 24,273 shares during the period. Systematic Financial Management LP owned 0.61% of Catalyst Pharmaceuticals worth $18,509,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CPRX. Advisory Services Network LLC purchased a new position in shares of Catalyst Pharmaceuticals in the 3rd quarter valued at approximately $39,000. Quarry LP purchased a new stake in shares of Catalyst Pharmaceuticals during the third quarter worth approximately $40,000. Clearstead Advisors LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 192.9% during the fourth quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 1,167 shares during the period. Smartleaf Asset Management LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 55.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 630 shares during the period. Finally, Larson Financial Group LLC grew its position in Catalyst Pharmaceuticals by 552.7% in the 4th quarter. Larson Financial Group LLC now owns 1,847 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 1,564 shares during the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Stock Performance

CPRX stock opened at $31.49 on Friday. The firm has a 50 day moving average of $31.38 and a 200-day moving average of $27.27. The company has a market cap of $3.86 billion, a price-to-earnings ratio of 18.10, a PEG ratio of 0.96 and a beta of 0.74. Catalyst Pharmaceuticals, Inc. has a 12-month low of $19.05 and a 12-month high of $32.56.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Citigroup downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $35.00 to $31.50 in a research report on Friday, May 8th. Zacks Research lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 18th. HC Wainwright cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the stock from $35.00 to $31.50 in a report on Thursday, May 28th. Oppenheimer lowered Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, May 7th. Finally, Stephens set a $32.00 target price on Catalyst Pharmaceuticals in a research report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).